Held by 4 specialist biotech funds
High Convergence**Signal Note: OrbiMed Entry into ANRO** OrbiMed's $2.2M initiating position suggests conviction in Alto's clinical-stage pipeline, likely driven by upcoming data readouts in their lead program for treatment-resistant depression (TRD) and/or major depressive disorder.
AI analyst context — unlock full analysis
**SIGNAL NOTE: Commodore Capital initiates $32.5M ANRO position** Pellini's entry into Alto signals confidence in ANRO's pipeline of precision psychiatry assets, particularly ALTO-100 (a selective serotonin 7 receptor agonist) for major depressive disorder, which is progressing through late-stage development with potential catalysts in 2025-2026. This aligns with Pellini's track record identifying undervalued oncology precision diagnostics at Foundation Medicine, suggesting he sees similar value creation potential in psychiatric biomarkers and targeted CNS therapeutics. The $32.5M stake (~2.9% ownership) represents meaningful conviction in a sub-$1.2B market cap name, indicating institutional appetite for de-risked neuroscience assets ahead of key Phase 3 readouts.
+ 2more — see how much conviction went in
See the Full Story